Amarillo Biosciences, Inc. (“we,” “ABI” or the “Company”), (OTC PINK:AMAR), a company engaged in low-dose non-injectable interferon research, announced today that it has entered into a Securities Purchase Agreement (“Agreement”) with a strategic investor, Ainos, Inc., a Cayman Islands corporation (“Ainos”) focused on advanced technology diagnostic medical devices and artificial intelligence consumer healthcare solutions
December 30, 2020
· 9 min read